1.Relationship between life meaning and life satisfaction among university students
Kai ZHANG ; Shoubao WU ; Jianping ZHONG
Chinese Journal of Behavioral Medicine and Brain Science 2012;21(4):367-369
ObjectiveTo investigate the relationship between life meaning and life satisfaction among university students.MethodsTotally 473 university students were investigated with The Purpose In Life Test and Life Satisfaction Scale.Results ( 1 ) The scores of life satisfaction and positive affection in highcr levels of life meaning were significantly higher than those in the lower levels of life meaning( (4.53 ± 1.04)vs(3.38 ± 0.98 ),(2.89 ±0.88)vs(2.04 ± 1.07) ) among the university students(F=27.806,P<0.01 ; F=13.635,P< 0.01 ),however the higher levels of life meaning were significantly lower than the lower levels of life meaning ( ( 1.09 ± 1.12 ) vs ( 2.45 ± 1.41 ) ) in negative affection (F =21.513,P < 0.01 ).( 2 ) The students' life satisfaction was negatively correlated with escape( r=-0.336,P<0.01 ).The others factors of life meaning were positively correlated with life satisfaction ( r =0.285 ~ 0.380,P < 0.01 ).The negative affection was negatively correlated with life meaning( r =-0.121 ~ -0.335,P < 0.05 ).(3)The escape had significantly negative prediction on life satisfaction and positive affection ( β =-0.133 ~ -0.179,P < 0.05 ).The life of goals and the life of passion had significantly positive prediction on life satisfaction and positive affection ( β =0.170 ~ 0.206,P < 0.05 ).Conclusion Life meaning of the university students is closely related to life satisfaction,the higher levels of life meaning can upgrade individual life satisfaction.
2.Roles of inflammatory cytokines in acute graft-versus-host disease and their mechanisms
Shuangzhu LIU ; Shoubao MA ; Haiyan LIU ; Depei WU ;
Chinese Journal of Microbiology and Immunology 2017;37(1):78-82
Allogeneic hematopoietic stem cell transplantation ( allo-HSCT) is an effective therapy for the treatment of various malignant and non-malignant hematological diseases. Acute graft-verse-host-dis-ease ( aGVHD) , a major complication following allo-HSCT, is one of the predominant causes of GVHD-re-lated mortality. The development of aGVHD is a typical pathologic process with the release of inflammatory cytokines in great quantities, resulting in the occurrence ofcytokine storm and causing specific pathologi-cal damages by attacking the recipient organ. Therefore, identification of biomarkers specific for aGVHD of-fers promise to the treatment of aGVHD. In this review, we summarizes the functions of several typical in-flammatory cytokines, including IL-1β, IL-6, IL-17A and IL-10, and their mechanisms in the development of aGVHD in order to provide references for the prevention and treatment of aGVHD.
3.Interleukin-27:a biomarker for prediction of acute graft-versus-host disease after allogeneic hemato-poietic stem cell transplantation from unrelated donors
Shuangzhu LIU ; Jingjing HAN ; Huanle GONG ; Jiaqian QI ; Hong LIU ; Jia CHEN ; Shoubao MA ; Depei WU
Chinese Journal of Microbiology and Immunology 2018;38(2):98-105
Objective To analyze the predictive value of serum interleukin-27 (IL-27) for acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) from unrelated donors. Methods Serum samples were collected from 72 patients after receiving allo-HSCT from unrelated donors during January to December 2012. Serum samples collected from 70 patients received allo-HSCT in 2013 were used for confirmation. All patients received myeloablative conditioning regimen prior to allo-HSCT. Cyclosporin A (CsA)+mycophenolate mofetil (MMF)+short-term methotrexate (MTX) were used for GVHD prophylaxis. Serum IL-27 levels in patients with aGVHD were measured by ELISA. The pre-dictive value of IL-27 index,defined as the ratio of serum IL-27 level at neutrophil engraftment to that before pre-conditioning regimen, for allogeneic HSCT was retrospectively analyzed. Results Serum IL-27 index was significantly decreased in patients with gradeⅡ-ⅣaGVHD(grade 0-Ⅰ : 1.89±0.68 vs gradeⅡ-Ⅳ :1.26±0.49;P<0.000 1). IL-27 index had good value for grade Ⅱ-Ⅳ aGVHD (AUC=0.782,95% CI:0.675-0.889,P<0.001). Patients with a lower serum IL-27 index (<1.33) were more likely to have a higher cumulative incidence of grade Ⅱ-Ⅳ aGVHD than those with a higher serum IL-27 index (P<0.001). Multivariate analysis confirmed that low IL-27 index was the most significant risk factor for gradeⅡ-Ⅳ aGVHD (HR=4.50,95% CI:2.1-9.8,P<0.01). These findings were consistent with the results found in the serum samples collected in 2013. Conclusion Low IL-27 index could be used to predict the incidence of grade Ⅱ-Ⅳ acute GVHD after allo-HSCT from unrelated donors.
4.Antihyperuricemic effect of mangiferin aglycon derivative J99745 by inhibiting xanthine oxidase activity and urate transporter 1 expression in mice.
Zhizhen QIN ; Shoubao WANG ; Yihuang LIN ; Ying ZHAO ; Shengqian YANG ; Junke SONG ; Tao XIE ; Jinlong TIAN ; Song WU ; Guanhua DU
Acta Pharmaceutica Sinica B 2018;8(2):306-315
A mangiferin aglycon derivative J99745 has been identified as a potent xanthine oxidase (XOD) inhibitor by previous study. This study aimed to evaluate the hypouricemic effects of J99745 in experimental hyperuricemia mice, and explore the underlying mechanisms. Mice were orally administered 600 mg/kg xanthine once daily for 7 days and intraperitoneally injected 250 mg/kg oxonic acid on the 7th day to induce hyperuricemia. Meanwhile, J99745 (3, 10, and 30 mg/kg), allopurinol (20 mg/kg) or benzbromarone (20 mg/kg) were orally administered to mice for 7 days. On the 7th day, uric acid and creatinine in serum and urine, blood urea nitrogen (BUN), malondialdehyde (MDA) content and XOD activities in serum and liver were determined. Morphological changes in kidney were observed using hematoxylin and eosin (H&E) staining. Hepatic XOD, renal urate transporter 1 (URAT1), glucose transporter type 9 (GLUT9), organic anion transporter 1 (OAT1) and ATP-binding cassette transporter G2 (ABCG2) were detected by Western blot and real time polymerase chain reaction (PCR). The results showed that J99745 at doses of 10 and 30 mg/kg significantly reduced serum urate, and enhanced fractional excretion of uric acid (FEUA). H&E staining confirmed that J99745 provided greater nephroprotective effects than allopurinol and benzbromarone. Moreover, serum and hepatic XOD activities and renal URAT1 expression declined in J99745-treated hyperuricemia mice. In consistence with the ability to inhibit XOD, J99745 lowered serum MDA content in hyperuricemia mice. Our results suggest that J99745 exerts urate-lowering effect by inhibiting XOD activity and URAT1 expression, thus representing a promising candidate as an anti-hyperuricemia agent.